A Phase II Study of Ribociclib And Endocrine Treatment of Physician s Choice for Locoregional Recurrent Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)

Brief description of study

Primary Objective: To estimate subsequent recurrence-free survival (RFS) at 3 years for ribociclib when administered with ET (AIs or fulvestrant), in patients with Hormone Receptor (HR) positive, HER2 negative breast cancer with adequately resected local recurrence of early breast cancer (EBC). Secondary Objectives: To estimate distant metastasis-free survival To estimate overall survival (OS). To evaluate safety and tolerability To identify predictors of loco-regional recurrence.

Clinical Study Identifier: s22-00921

ClinicalTrials.gov Identifier: NCT05467891

Principal Investigator: Nancy Chan.

Other Investigators: Caitlin Elizabeth Ordonez Ferri, Yelena Novik, Maryann J Kwa, Theresa Ryan, Marleen I Meyers, Jennifer Wu, Cristian C Papazoglu Statescu, Neil Vasan, Andrea Popescu-Martinez, Wanqing Iris Zhi, Danielle Seidman, Amanda Marie Buzolich, Anastasiya Apanasyuk, Alexander A Hindenburg, Ruth Oratz, Natalie Jill Klar, Mary Lynn R Nierodzik, Douglas K Marks.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies